Committed to sharing our science

Committed to sharing our science

scientist testing potential medicines

327 results available

Pharmacokinetics, Mass Balance, Tissue Distribution, Metabolism, and Excretion of [14C]Aficamten Following Single Oral Dose Administration to Rats

Xenobiotica

Grillo, MP et al

July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

Journal of the American Heart Association

Coats, CJ et al

July 26, 2024
Safety and Efficacy of Aficamten in Patients With Non-obstructive Hypertrophic Cardiomyopathy: A 36-week Analysis From FOREST-HCM

European Journal of Heart Failure

Masri, A et al

July 18, 2024
Discovery of Aficamten (CK-274): Next-in-class Cardiac myosin inhibitor (CMI) for obstructive Hypertrophic Cardiomyopathy (oHCM)

Oral Presentation, Drug Discovery Nexus (DDN) 2024

Chuang, G

May 8, 2024
Associations Between Sex and Cardiovascular Outcomesin Patients with Hypertrophic Cardiomyopathy

Poster, European Society of Cardiology Heart Failure (ESC-HF) 2024

Reza, N et al

May 13, 2024